News

ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences

Third Quarter Earnings Conference Call to be Held on November 13 at 8:00 a.m. ETSAN DIEGO, Nov. 06, 2024 (GLOBE…

3 weeks ago

Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and…

3 weeks ago

Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13

DALLAS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing…

3 weeks ago

LifeMD® Launches Affiliated Pharmacy to Drive End-to-End Patient Care and Operational Efficiency

State-of-the-Art Pharmacy Completes LifeMD’s End-to-end Healthcare Platform, Supporting 5,000 Daily Orders, Improving Operating Margins, and Enabling Curated Care JourneysNEW YORK,…

3 weeks ago

EDAP to Participate in the 2024 Jefferies London Healthcare Conference

          LYON, France, November 6, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in…

3 weeks ago

Pliant Therapeutics to Participate in the Stifel Healthcare Conference

SOUTH SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that Keith Cummings, M.D.,…

3 weeks ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

– Topline data from pivotal Phase 3 TANDEM trial now expected in 4Q 2024 due to faster than expected enrollment…

3 weeks ago

Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality

NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel…

3 weeks ago

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron –MELBOURNE, AUSTRALIA and SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE)…

3 weeks ago

Quell Therapeutics to Participate at Upcoming Healthcare Investor Conferences

London, UK – November 6, 2024 – Quell Therapeutics Ltd (“Quell”), a world leader in developing engineered T-regulatory (Treg) cell…

3 weeks ago